Projectes destacats

Red transpirenaica de terapias avanzadas en linfoma no Hodgkin (THERAVLINFO)

Investigador/a principal: Patricia Pérez Galán.
Finançador: POCTEFA-INTERREG, European Union.

Codi: EFA 123/1.

Durada: 01/01/2024 - 31/12/2025
Vascularized lymphoma on-chip: a multifaceted tool for translational research (MyLymphoTool)

Investigador/a principal: Patricia Pérez Galán.
Finançador: Fundació La Caixa.

Codi: HR22-00395.

Durada: 01/12/2022 - 30/11/2025
Dual CD19-CAR-T approaches to counteract antigen escape and tumor microenvironment immune suppression in FL

Investigador/a principal: Patricia Pérez Galán.
Finançador: Follicular Lymphoma Foundation.

Codi: INT_Milken_FLF_22.

Durada: 01/12/2022 - 30/11/2024
Vascular and extracellular matrix remodeling in follicular lymphoma: implications in the transformation to an aggressive lymphoma and immunotherapy efficacy (VASCEM_LYMPHO)

Investigador/a principal: Patricia Pérez Galán.
Finançador: Agencia Estatal de Investigacion (AEI).

Codi: PID2021-124894OB-I00.

Durada: 01/09/2022 - 31/08/2025
Patient Derived Organoids 2.0: Annotated immunocompetent organoid platforms in solid and hematological tumors as living labs for the optimization and design of current and novel immunotherapies and cellular therapies. CIBERONC (Strategic Action-Towards Ca

Investigador/a principal: Patricia Pérez Galán.
Durada: 01/07/2021 - 01/07/2023
Characterization of duvelisib activity in follicular lymphoma and macrophages crosstalk

Investigador/a principal: Patricia Pérez Galán.
Finançador: Janssen Pharmaceuticals.

Durada: 01/01/2020 - 31/12/2020
Multi-cellular interactions in the progression of chronic inflammatory diseases and lymphoproliferative disorders: 3D models to investigate targeted immune therapies -3DIMMUNETARGET

Investigador/a principal: Maria Cinta Cid Xutgla, Patricia Pérez Galán.
Finançador: Ministerio de Economia y Competitividad (MINECO).

Codi: SAF 2017- 88275-R.

Durada: 01/01/2018 - 31/12/2020
Cross-border network of personalized immunotherapies in Non-Hodgkin Lymphoma -IMLINFO (POCTEFA-INTERREG).

Investigador/a principal: Patricia Pérez Galán.
Finançador: INTERREG V-POCTEFA.

Codi: EFA281/16.

Durada: 01/01/2018 - 31/12/2021
Crosstalk between lymphocytes and their microenvironment in chronic inflammatory diseases and lymphoproliferative disorders as a target for new therapeutic intervention

Investigador/a principal: Patricia Pérez Galán.
Finançador: Ministerio de Economía y Competitividad.

Codi: SAF 2014/57708R.

Durada: 01/01/2015 - 01/01/2018
Characterization of the mechanisms of microenvironment-derived resistance to GS-1101/ Idelalisib in follicular lymphoma. Analysis of therapeutic potential combination with other kinases inhibitors

Investigador/a principal: Patricia Pérez Galán.
Finançador: Gilead.

Durada: 01/07/2014

La recerca d'aquest grup es pot dur a terme gràcies als finançadors.

Projectes destacats

Red transpirenaica de terapias avanzadas en linfoma no Hodgkin (THERAVLINFO)

Vascularized lymphoma on-chip: a multifaceted tool for translational research (MyLymphoTool)

Dual CD19-CAR-T approaches to counteract antigen escape and tumor microenvironment immune suppression in FL

Vascular and extracellular matrix remodeling in follicular lymphoma: implications in the transformation to an aggressive lymphoma and immunotherapy efficacy (VASCEM_LYMPHO)

Patient Derived Organoids 2.0: Annotated immunocompetent organoid platforms in solid and hematological tumors as living labs for the optimization and design of current and novel immunotherapies and cellular therapies. CIBERONC (Strategic Action-Towards Ca

Characterization of duvelisib activity in follicular lymphoma and macrophages crosstalk

Multi-cellular interactions in the progression of chronic inflammatory diseases and lymphoproliferative disorders: 3D models to investigate targeted immune therapies -3DIMMUNETARGET

Cross-border network of personalized immunotherapies in Non-Hodgkin Lymphoma -IMLINFO (POCTEFA-INTERREG).

Crosstalk between lymphocytes and their microenvironment in chronic inflammatory diseases and lymphoproliferative disorders as a target for new therapeutic intervention

Characterization of the mechanisms of microenvironment-derived resistance to GS-1101/ Idelalisib in follicular lymphoma. Analysis of therapeutic potential combination with other kinases inhibitors

Finançadors principals